FDA Sounds Off On Unapproved Ear Drops Through Enforcement Notice
This article was originally published in The Tan Sheet
Executive Summary
FDA says firms marketing unapproved and misbranded prescription otic products containing one or more of antipyrine, benzocaine, chloroxylenol, hydrocortisone, pramoxine and zinc acetate will be subject to enforcement actions including seizure, injunction and/or criminal proceedings.
You may also be interested in...
FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
FDA plans to increase enforcement actions against marketed unapproved drugs in the coming year, but hopes to cooperate with firms willing to come to the table seeking approval for currently unapproved products
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.